Inflammation and infection in exacerbations of chronic obstructive pulmonary disease

Seminars in Respiratory Infections

Volumn 18, Issue 1, 2003, Pages 9-16

  Pietila, Michael P ^a   Thomas, Charles F ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ALPHA 1 ANTITRYPSIN; ANTIBIOTIC AGENT; BRONCHODILATING AGENT; CARBOCISTEINE; CORTICOSTEROID; MECYSTEINE; MUCOLYTIC AGENT;

ALPHA 1 ANTITRYPSIN DEFICIENCY; ASTHMA; BACTERIAL INFECTION; CHLAMYDIASIS; CHRONIC BRONCHITIS; CHRONIC LUNG DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; DISEASE EXACERBATION; EMPHYSEMA; EOSINOPHIL; FORCED EXPIRATORY VOLUME; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; INFLAMMATION; LUNG FUNCTION; LYMPHOCYTE; MACROPHAGE; MYCOPLASMA; NEUTROPHIL; OXIDATIVE STRESS; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; REVIEW; RHINOVIRUS; SMOKING CESSATION; VIRUS INFECTION;

HUMANS; INFLAMMATION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY TRACT INFECTIONS;

EID: 0037348218     PISSN: 08820546     EISSN: None     Source Type: Journal    
DOI: 10.1053/srin.2003.50007     Document Type: Review

References (74)

1. Siafakas NM, Vermeire P, Pride NB, et al: Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. Eur Respir J 8:1398-1420, 1995
2. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. American Thoracic Society. Am J Respir Crit Care Med 152:S77-S121, 1995
3. Benson V, Marano MA: Current estimates from the National Health Interview Survey, 1995. Vital Health Stat 10:1-428, 1998
4. Snider GL: Chronic obstructive pulmonary disease: Risk factors, pathophysiology and pathogenesis. Annu Rev Med 40:411-429, 1989
5. 1. The Lung Health Study. JAMA 272:1497-1505, 1994
6. Tashkin DP, Altose MD, Bleecker ER, et al: The lung health study: Airway responsiveness to inhaled methacholine in smokers with mild to moderate airflow limitation. The Lung Health Study Research Group. Am Rev Respir Dis 145:301-310, 1992
7. Shapiro SD: End-stage chronic obstructive pulmonary disease: The cigarette is burned out but inflammation rages on. Am J Respir Crit Care Med 164:339-340, 2001
8. Rutgers SR, Postma DS, ten Hacken NH, et al: Ongoing airway inflammation in patients with COPD who do not currently smoke. Thorax 55:12-18, 2000
9. Guidelines for the approach to the patient with severe hereditary α-1-antitrypsin deficiency. American Thoracic Society. Am Rev Respir Dis 140:1494-1497, 1989
10. Oxman AD, Muir DC, Shannon HS, et al: Occupational dust exposure and chronic obstructive pulmonary disease. A systematic overview of the evidence. Am Rev Respir Dis 148:38-48, 1993
11. Jeffery PK: Structural and inflammatory changes in COPD: A comparison with asthma. Thorax 53:129-136, 1998
12. Gompertz S, Stockley RA: Inflammation - role of the neutrophil and the eosinophil. Semin Respir Infect 15: 14-23, 2000
13. Barnes PJ: Mechanisms in COPD: Differences from asthma. Chest 117:10S-14S, 2000
14. Balbi B, Bason C, Balleari E, et al: Increased bronchoalveolar granulocytes and granulocyte/macrophage colony-stimulating factor during exacerbations of chronic bronchitis. Eur Respir J 10:846-850, 1997
15. Saetta M, Di Stefano A, Maestrelli P, et al: Airway eosinophilia in chronic bronchitis during exacerbations. Am J Respir Crit Care Med 150:1646-1652, 1994
16. Keatings VM, Collins PD, Scott DM, et al: Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med 153:530-534, 1996
17. Pesci A, Balbi B, Majori M, et al: Inflammatory cells and mediators in bronchial lavage of patients with chronic obstructive pulmonary disease. Eur Respir J 12:380-386, 1998
18. Crooks SW, Bayley DL, Hill SL, et al: Bronchial inflammation in acute bacterial exacerbations of chronic bronchitis: The role of leukotriene B4. Eur Respir J 15:274-280, 2000
19. Riise GC, Larsson S, Lofdahl CG, et al: Circulating cell adhesion molecules in bronchial lavage and serum in COPD patients with chronic bronchitis. Eur Respir J 7:1673-1677, 1994
20. Eriksson S: Studies in α-1-antitrypsin deficiency. Acta Med Scand Suppl 432:1-85, 1965
21. Di Stefano A, Capelli A, Lusuardi M, et al: Severity of airflow limitation is associated with severity of airway inflammation in smokers. Am J Respir Crit Care Med 158:1277-1285, 1998
22. Di Stefano A, Turato G, Maestrelli P, et al: Airflow limitation in chronic bronchitis is associated with T-lymphocyte and macrophage infiltration of the bronchial mucosa. Am J Respir Crit Care Med 153:629-632, 1996
23. Bhowmik A, Seemungal TA, Sapsford RJ, et al: Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax 55: 114-120, 2000
24. Totti N 3rd, McCusker KT, Campbell EJ, et al: Nicotine is chemotactic for neutrophils and enhances neutrophil responsiveness to chemotactic peptides. Science 223: 169-171, 1984
25. Senior RM, Griffin GL, Mecham RP: Chemotactic activity of elastin-derived peptides. J Clin Invest 66:859-862, 1980
26. Hunninghake GW, Davidson JM, Rennard S, et al: Elastin fragments attract macrophage precursors to diseased sites in pulmonary emphysema. Science 212:925-927, 1981
27. Hill A, Gompertz S, Stockley R: Factors influencing airway inflammation in chronic obstructive pulmonary disease. Thorax 55:970-977, 2000
28. Bingle L, Tetley TD: Secretory leukoprotease inhibitor: Partnering α-1-proteinase inhibitor to combat pulmonary inflammation. Thorax 51:1273-1274, 1996
29. Janoff A, Raju L, Dearing R: Levels of elastase activity in bronchoalveolar lavage fluids of healthy smokers and nonsmokers. Am Rev Respir Dis 127:540-544, 1983
30. Carp H, Miller F, Hoidal JR, et al: Potential mechanism of emphysema: α-1-proteinase inhibitor recovered from lungs of cigarette smokers contains oxidized methionine and has decreased elastase inhibitory capacity. Proc Natl Acad Sci U S A 79:2041-2045, 1982
31. Gompertz S, Bayley DL, Hill SL, et al: Relationship between airway inflammation and the frequency of exacerbations in patients with smoking related COPD. Thorax 56:36-41, 2001
32. Parks WC, Shapiro SD: Matrix metalloproteinases in lung biology. Respir Res 2:10-19, 2001
33. Shapiro SD, Senior RM: Matrix metalloproteinases. Matrix degradation and more. Am J Respir Cell Mol Biol 20:1100-1102, 1999
34. Merchant RK, Schwartz DA, Helmers RA, et al: Bronchoalveolar lavage cellularity. The distribution in normal volunteers. Am Rev Respir Dis 146:448-453, 1992
35. Finlay GA, O'Driscoll LR, Russell KJ, et al: Matrix metalloproteinase expression and production by alveolar macrophages in emphysema. Am J Respir Crit Care Med 156:240-247, 1997
36. Adams DH, Lloyd AR: Chemokines: Leucocyte recruitment and activation cytokines. Lancet 349:490-495, 1997
37. Shapiro SD: Elastolytic metalloproteinases produced by human mononuclear phagocytes. Potential roles in destructive lung disease. Am J Respir Crit Care Med 150: S160-S164, 1994
38. Chapman HA Jr, Munger JS, Shi GP: The role of thiol proteases in tissue injury and remodeling. Am J Respir Crit Care Med 150:S155-S159, 1994
39. Hautamaki RD, Kobayashi DK, Senior RM, et al: Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice. Science 277:2002-2004, 1997
40. D'Armiento J, Dalal SS, Okada Y, et al: Collagenase expression in the lungs of transgenic mice causes pulmonary emphysema. Cell 71:955-961, 1992
41. Farrelly N, Lee YJ, Oliver J, et al: Extracellular matrix regulates apoptosis in mammary epithelium through a control on insulin signaling. J Cell Biol 144:1337-1348, 1999
42. Kataoka H, Uchino H, Iwamura T, et al: Enhanced tumor growth and invasiveness in vivo by a carboxyl-terminal fragment of alpha1-proteinase inhibitor generated by matrix metalloproteinases: A possible modulatory role in natural killer cytotoxicity. Am J Pathol 154:457-468, 1999
43. O'Shaughnessy TC, Ansari TW, Barnes NC, et al: Inflammation in bronchial biopsies of subjects with chronic bronchitis: Inverse relationship of CD8+ T lymphocytes with FEV1. Am J Respir Crit Care Med 155: 852-857, 1997
44. Saetta M, Di Stefano A, Turato G, et al: CD8+ T-lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 157:822-826, 1998
45. Repine JE, Bast A, Lankhorst I: Oxidative stress in chronic obstructive pulmonary disease. Oxidative Stress Study Group. Am J Respir Crit Care Med 156:341-357, 1997
46. Maier KL, Leuschel L, Costabel U: Increased oxidized methionine residues in BAL fluid proteins in acute or chronic bronchitis. Eur Respir J 5:651-658, 1992
47. Barnes PJ: New therapies for chronic obstructive pulmonary disease. Thorax 53:137-147, 1998
48. Barnes PJ: Chronic obstructive pulmonary disease. N Engl J Med 343:269-280, 2000
49. Luisetti M, Sturani C, Sella D, et al: MR889, a neutrophil elastase inhibitor, in patients with chronic obstructive pulmonary disease: A double-blind, randomized, placebo-controlled clinical trial. Eur Respir J 9:1482-1486, 1996
50. Niewoehner DE, Erbland ML, Deupree RH, et al: Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N Engl J Med 340: 1941-1947, 1999
51. Paggiaro PL, Dahle R, Bakran I, et al: Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group. Lancet 351:773-780, 1998
52. Culpitt SV, Maziak W, Loukidis S, et al: Effect of high dose inhaled steroid on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 160:1635-1639, 1999
53. Compton CH, Gubb J, Nieman R, et al: Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: A randomised, dose- ranging study. Lancet 358:265-270, 2001
54. Xu J, Clark RA, Parks WC: p38 mitogen-activated kinase is a bidirectional regulator of human fibroblast collagenase-1 induction by three-dimensional collagen lattices. Biochem J 355:437-447, 2001
55. Underwood DC, Osborn RR, Bochnowicz S, et al: SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung. Am J Physiol Lung Cell Mol Physiol 279:L895-L902, 2000
56. Barnes PJ: Novel approaches and targets for treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 160:S72-S79, 1999
57. Wilson R: Evidence of bacterial infection in acute exacerbations of chronic bronchitis. Semin Respir Infect 15: 208-215, 2000
58. Monso E, Ruiz J, Rosell A, et al: Bacterial infection in chronic obstructive pulmonary disease. A study of stable and exacerbated outpatients using the protected specimen brush. Am J Respir Crit Care Med 152:1316-1320, 1995
59. Miravitlles M, Espinosa C, Fernandez-Laso E, et al: Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Study Group of Bacterial Infection in COPD. Chest 116:40-46, 1999
60. Soler N, Torres A, Ewig S, et al: Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation. Am J Respir Crit Care Med 157:1498-1505, 1998
61. Eller J, Ede A, Schaberg T, et al: Infective exacerbations of chronic bronchitis: Relation between bacteriologic etiology and lung function. Chest 113:1542-1548, 1998
62. Sethi S: Bacterial infection and the pathogenesis of COPD. Chest 117:286S-291S, 2000
63. Saint S, Bent S, Vittinghoff E, et al: Antibiotics in chronic obstructive pulmonary disease exacerbations. A meta-analysis. JAMA 273:957-960, 1995
64. Bach PB, Brown C, Gelfand SE, et al: Management of acute exacerbations of chronic obstructive pulmonary disease: A summary and appraisal of published evidence. Ann Intern Med 134:600-620, 2001
65. Anthonisen NR, Manfreda J, Warren CP, et al: Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 106:196-204, 1987
66. Ball P, Harris JM, Lowson D, et al: Acute infective exacerbations of chronic bronchitis. QJM 88:61-68, 1995
67. Adams SG, Anzueto A: Antibiotic therapy in acute exacerbations of chronic bronchitis. Semin Respir Infect 15:234-247, 2000
68. Ball P: Epidemiology and treatment of chronic bronchitis and its exacerbations. Chest 108:43S-52S, 1995
69. Stockley RA, O'Brien C, Pye A, et al: Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest 117:1638-1645, 2000
70. Von Hertzen L, Alakarppa H, Koskinen R, et al: Chlamydia pneumoniae infection in patients with chronic obstructive pulmonary disease. Epidemiol Infect 118: 155-164, 1997
71. Theegarten D, Mogilevski G, Anhenn O, et al: The role of chlamydia in the pathogenesis of pulmonary emphysema. Electron microscopy and immunofluorescence reveal corresponding findings as in atherosclerosis. Virchows Arch 437:190-193, 2000
72. Retamales I, Elliott WM, Meshi B, et al: Amplification of inflammation in emphysema and its association with latent adenoviral infection. Am J Respir Crit Care Med 164:469-473, 2001
73. Hogg JC: Latent adenoviral infection in the pathogenesis of emphysema: The Parker B. Francis Lectureship. Chest 117:282S-285S, 2000
74. Seemungal TA, Harper-Owen R, Bhowmik A, et al: Detection of rhinovirus in induced sputum at exacerbation of chronic obstructive pulmonary disease. Eur Respir J 16:677-683, 2000